Recent Updates
Recently added Catalysts
KPTI

Karyopharm to Present at B. Riley Securities Oncology Investor Conference

Key Takeaway: NEWTON, Mass., Jan. 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present virtually
Price reaction · baseline $115.95 (2022-01-20 close) · hit after-hours · 1 other KPTI headline(s) in the window, move may be shared
day 0 close
+7.1%
day 1
+10.3%
day 3 · peak
+12.3%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+105%
120-day peak, hindsight
Typical move
15.1%
average across 5 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
Selinexor
Phase 2 · Acute Myeloid Leukemia (AML)

Full Press Release Details

NEWTON, Mass., Jan. 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present virtually at the B. Riley Securities Oncology Investor Conference. The conference is being conducted in a virtual format and the presentation will take place on Friday, January 28 at 9:30 a.m. ET.
A live webcast of the presentation, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 30 days following the event.
About Karyopharm Therapeutics
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
Last updated: Jan 21, 2022